Emerging biomarkers in thyroid practice and research
Simple Summary Tumor biomarkers are molecules at genetic or protein level, or certain
evaluable characteristics. These help in perfecting patient management. Over the past …
evaluable characteristics. These help in perfecting patient management. Over the past …
Immunohistochemistry helps to distinguish noninvasive follicular thyroid neoplasm with papillary-like nuclear features/noninvasive encapsulated follicular variant of …
HW Chuang, JS Wang, JW Tsai, CT Hsu, KJ Lin - Medicina, 2021 - mdpi.com
Background and Objectives: We aimed to assess the diagnostic value of various
immunohistochemical (IHC) markers and panels for differentiation among benign follicular …
immunohistochemical (IHC) markers and panels for differentiation among benign follicular …
[HTML][HTML] Challenge in the pathological diagnosis of the follicular-patterned thyroid lesions
Background: The follicular-patterned thyroid lesions (FPTLs) include hyperplastic nodules
(HN), follicular adenoma (FA), non-invasive follicular neoplasm with papillary-like nuclear …
(HN), follicular adenoma (FA), non-invasive follicular neoplasm with papillary-like nuclear …
Utility of Immunohistochemistry Markers CK19, Gal-3, HBME-1 and Their Combinations for Differential Diagnosis of Thyroid Diseases
A Dağlar Aday, H Demir, T Öztürk - Indian Journal of Surgery, 2023 - Springer
Differential diagnosis is important for clinical management of cases with thyroid diseases.
We aimed to find the most useful diagnostic panel including immunohistochemistry markers …
We aimed to find the most useful diagnostic panel including immunohistochemistry markers …
Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid
PA Prasad, K Raju - Journal of Cancer Research and …, 2022 - journals.lww.com
Background: Thyroid neoplasm is one of the most common endocrine neoplasms. The
diagnosis and the distinction between malignant and benign neoplasms can be difficult, but …
diagnosis and the distinction between malignant and benign neoplasms can be difficult, but …
Diagnostic role of immunohistochemical markers CK19 and CD56 in thyroid neoplasms
P Priyadarshini, MK Patro, PK Das - MGM Journal of Medical …, 2023 - journals.lww.com
Materials and Methods: Total/hemithyroidectomy specimens received in the Department of
Pathology, Maharaja Krushna Chandra Gajapati Medical College and Hospital, Brahmapur …
Pathology, Maharaja Krushna Chandra Gajapati Medical College and Hospital, Brahmapur …
The diagnostic utility of INSM1 and GATA3 in discriminating problematic medullary thyroid carcinoma, thyroid and parathyroid lesions
SA Hakim, NM Abd Raboh - Polish Journal of Pathology, 2021 - termedia.pl
Discriminating thyroid and parathyroid lesions may sometimes pose a diagnostic difficulty.
Medullary thyroid carcinomas (MTCs) display various cytologic and architectural features …
Medullary thyroid carcinomas (MTCs) display various cytologic and architectural features …
[HTML][HTML] BRAF V600E, p53, CD56, CK19, Galectin-3, TPO 在247 例甲状腺乳头状癌的表达与诊断价值
胡诗梦, 王敏 - Advances in Clinical Medicine, 2022 - hanspub.org
目的: 探讨甲状腺乳头状癌(papillary thyroid carcinoma, PTC) 的BRAF V600E, p53, CD56,
CK19, Galectin-3, TPO 的表达及诊断价值. 方法: 选取2019 年12 月至2021 年12 …
CK19, Galectin-3, TPO 的表达及诊断价值. 方法: 选取2019 年12 月至2021 年12 …
Application of immunohistochemistry in papillary thyroid carcinoma
Immunohistochemistry (IHC) is an economic and precise method to localize the presence of
specific protein at cellular level in tissue. Although many papillary thyroid carcinomas do not …
specific protein at cellular level in tissue. Although many papillary thyroid carcinomas do not …
Expression of CD10 and CD56 in Benign and Malignant Thyroid Lesions
SA MAHMOUD, AG HUSSIEN… - The Medical Journal of …, 2022 - journals.ekb.eg
Background: CD 10 was initially recognised as a cell–sur-face antigen expressed by acute
lymphoblastic leukaemias, and hence it's early designation as Common Acute Lymphob …
lymphoblastic leukaemias, and hence it's early designation as Common Acute Lymphob …